Hutchmed Share News (HCM)

Hutchison China Meditech 2018 Loss Widens On New Government Policy

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to

Hutchison Chi-Med enters four new drug test collaborations

(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.

Hutchison China Meditech Starts Fruquintinib Capsules Sales In China

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said it launched fruquintinib capsules Elunate with the initiation of product sales in China.Elunate is used for the of with

SVM UK Emerging Fund Beats Benchmark With Three Key Holdings

LONDON (Alliance News) - SVM UK Emerging Fund PLC on Monday said it had outpaced its benchmark in its most recent half year due to strong performances from three key holdings.As at 30, the

Hutchison China Meditech Starts Phase I Study For Leukemia In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Thursday it commenced a phase I study of HMPL-523 to treat elderly patients with acute myeloid leukemia in China.The aim of the is

Hutchison Gains Fruquintinib Capsules Approval As Cancer Drug In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Wednesday it gained Chinese approval for its Fruquintinib capsules to be used as treatment for metastatic colorectal cancer.The of

Hutchinson China Meditech Swings To Net Loss, Ups Annual Loss Estimate

LONDON (Alliance News) - Hutchison China Meditech Ltd on Friday raised its annual loss estimate by USD20 million after swinging to an interim net loss.For the six months to June 30, the a a

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 23 July Ryanair HoldingsQ1 ResultsAscentialHalf Year Retail GroupHalf 24

Hutchison China Cancer Trial Shows Clinically Meaningful Benefits

LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically at

UK Shareholder Meetings Calendar - Next 7 Days

Monday 23 AprilForeign & Colonial Investment Trust BioquellMicrogenHgCapital

Hutchison China Meditech 2017 Loss Widens Amid Rising Research Costs

LONDON (Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Monday annual losses widened due to increased and

Hutchison China Meditech Begins New Study For Epitinib Treatment

LONDON (Alliance News) - Pharmaceutical firm Hutchison China Meditech Ltd has started a phase Ib/II proof-of-concept study for its proposed brain cancer treatment is being in

Hutchinson China Begins In-Human Trial Of Novel Inhibitor HMPL-453

Hutchison China Starts Phase One HMPL-523 Trials In China

DIRECTOR DEALINGS SUMMARY: Hutchison China Chair Buys US-Listed ADSs